{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-008231","form_type":"8-K","ticker":"BEAM","cik":"0001745999","company_name":"Beam Therapeutics Inc.","filed_at":"2022-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:04:02.109709+00:00","generated_at":"2026-06-25T22:32:37.874558+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Beam Therapeutics Q1 net loss $69.2M; cash $1.2B; pipeline on track for H2 2022","bullets":["Net loss $69.2M ($1.01 per share) vs $201.6M ($3.35) in Q1 2021 due to prior-year in-process R&D charge.","Cash, equivalents and marketable securities $1.2B as of March 31, 2022 (vs $965.6M at Dec 31, 2021).","R&D expenses $65.4M (excl. $155M Guide Therapeutics acquisition cost in Q1 2021); G&A $19.2M.","BEAM-101 enrollment, BEAM-102 IND, and BEAM-201 IND all on track for second half of 2022.","Initiated AUNT natural history study in sickle cell trait; appointed Manmohan Singh to exec leadership and Anne Marie Woodland as head of regulatory."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-008231","json":"https://secwatch.observer/filing/0000950170-22-008231.json","markdown":"https://secwatch.observer/filing/0000950170-22-008231.md","text":"https://secwatch.observer/filing/0000950170-22-008231.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1745999/000095017022008231/0000950170-22-008231-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1745999/000095017022008231/beam-20220509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T22:32:37.874558+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}